News

The most common indication worldwide for pediatric transplantation, biliary atresia is also the most common cause of chronic liver disease in newborns. In the US, about 42 percent of children ...
She’s a normal baby that wants to play and crawl around and roll around and laugh and hang on to her dad,” Olivia Dildine’s ...
Biliary atresia, also known as "extrahepatic ductopenia" and "progressive obliterative cholangiopathy" is a congenital or acquired disease of the liver and one of the principal forms of chronic ...
The causes of biliary atresia were unknown, so this is a major advance that will move the field of pediatric liver disease forward, says senior author Saul J. Karpen, MD, PhD, professor of ...
The precise underlying pathogenesis is unknown; what is known is that the extrahepatic biliary tree undergoes an inflammatory fibro-obliterative process, which then leads to cholestasis and liver ...
Jannah Watkins, a 7-year-old Sicklerville resident, died recently after battling biliary atresia, a liver disease, according ...
In 1974, Benjamin Landing, a pediatric pathologist, proposed that biliary atresia, as well as choledochal cyst and neonatal hepatitis, represented varied manifestations of a single basic disease ...
At two-months old, Audrey Huss developed biliary atresia where a blockage prevents bile from traveling from the liver to gallbladder. By August 2021, she her abdomen started to fill with liquid ...
Biliary atresia (BA) is a rare, progressive inflammatory disease of the biliary system that is the leading cause of neonatal cholestasis, characterised by fibrosis and obliteration of the bile ducts.
Biliary atresia is a rare disease that occurs when a delicate tree-like set of ducts that carry bile from the liver to the intestine becomes scarred and blocked. While some treatments can slow the ...
The indication for liver transplantation was biliary atresia in 44% of these patients, congenital metabolic disease in 25%, fulminant hepatic failure in 18%, liver cirrhosis in 5%, congenital ...
Currently, there is no FDA-approved treatment for biliary atresia, a rare pediatric liver disease. A4250 is a first-in-class ileal bile acid transporter (IBAT) inhibitor being developed for rare ...